Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Isradipine formula medicine tablet and application thereof

A technology of isradipine and formula, applied in the directions of drug combination, pharmaceutical formula, pill delivery, etc., can solve the problems of slow effect and long duration, and achieve the effect of good activity

Active Publication Date: 2014-06-18
CHONGQING CONQUER PHARML
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The drug works more slowly (2 to 4 weeks) and lasts longer

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Isradipine formula medicine tablet and application thereof
  • Isradipine formula medicine tablet and application thereof
  • Isradipine formula medicine tablet and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0013] The screening of embodiment 1 isradipine prescription drug tablet preparation conditions

[0014] 1. Screening of the types of disintegrants

[0015] Taking the particle shape, water content of the granules, the hardness of the plain tablet, and the dissolution curve as the investigation indicators, the dosage of the disintegrant was fixed at 5%, and the disintegrants sodium carboxymethyl starch and croscarmellose sodium were investigated. The formula is shown in Table 1, and the test results are shown in Table 2.

[0016] Table 1 Screening of the types of disintegrants (formulation quantity 50 tablets)

[0017]

[0018] Preparation method: Weigh the raw and auxiliary materials of the formula respectively, mix them evenly, add an appropriate amount of binder to make a suitable soft material, pass through a 30-mesh sieve to granulate, dry at (50±5)°C until the water content is less than 3.0%, and use a 30-mesh Sieve for granulation, add magnesium stearate, mix and c...

Embodiment 2

[0033] The preparation of embodiment 2 isradipine formula medicine tablet

[0034] Adopting is the preferred formula conclusion of embodiment 1, according to the formula described in table 6, take the raw and auxiliary materials of the prescription amount, mix uniformly, add an appropriate amount of 4% binder to make a suitable soft material, cross 30 mesh sieves for granulation, and Dry at 50±5)°C to moisture <3.0%, granulate with a 30-mesh sieve, add magnesium stearate, mix and compress into tablets, and spray; gastric-soluble film coating premix Opadry (295W680000, containing hypromellose Cellulose, polyethylene glycol, titanium dioxide), namely the drug test group I.

[0035] Formulation 1 of table 6 isradipine formulation drug tablet

[0036]

[0037] The raw materials were weighed according to the formula in Table 7, and the drug experiment group II was prepared by the above method.

[0038] Formulation 2 of table 7 isradipine formulation drug tablet

[0039]

...

Embodiment 3

[0043] Embodiment 3 Experimental drug is investigated to the activity of hypertension

[0044] 10 male Wistar-Kyoto (WKY) rats of SFP grade 6-8 weeks old, 60 male SHR rats of SFP grade 6-8 weeks old. )°C, relative humidity (55-4-5)%, free access to food and water, pre-raised for 1 week.

[0045] Grouping of Experimental Animals 50 SHRs were randomly divided into 6 groups, namely model control group, isradipine group, quercetin group and drug experimental group Ⅰ, Ⅱ, Ⅲ, and 10 Wistar-Kyoto rats were used as normal control (WKY) Group. Experimental animals in all groups were subjected to a forced gavage administration method, and the administration volume was 1ml / 100g body weight.

[0046] Dosage: the model control group and the normal control group were administered with normal saline, the isradipine group was administered with 50 mg / kg of isradipine, the quercetin group was administered with 50 mg / kg of isradipine, and the drug experimental group was administered with 50 mg / ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a glimepiride pharmaceutical composition tablet as well as a preparation method and an application thereof. In order to solve the problems of the glimepiride tablets, the invention provides a glimepiride pharmaceutical composition which is composed of two components, namely glimepiride and sorbitol. The glimepiride pharmaceutical composition tablet is longer in release time in the human body, and more stable in blood concentration than a common tablet; the composition medicine is applicable to the diabetic nephropathy, and also has a better insulin secretion promoting effect than that of a common glimepiride medicine tablet.

Description

technical field [0001] The present invention relates to a kind of combination medicine, more specifically relate to a kind of isradipine prescription medicine tablet and application thereof. technical background [0002] Isradipine (also known as: isradipine, iradipine), chemical name: isopropylmethyl(±)-4-(4-benzofurazanyl)-1,4-dihydro-2,6 -Dimethyl-3,6-pyridinedicarboxylate. It is a new type of dihydropyridine calcium channel blocker. Like other dihydropyridine drugs, it can effectively and selectively inhibit the contraction caused by depolarization by blocking the influx of transmembrane calcium ions. And play a role on cardiac muscle and vascular smooth muscle. This product has a strong vasodilator effect, but no heart inhibitory effect, and almost does not cause reflex tachycardia. Clinical and animal experiments have proved that the drug has obvious antihypertensive and anti-atherosclerotic effects. By maintaining or restoring the blood flow under the left ventricu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/4439A61K9/20A61P9/12A61P3/10A61P13/12A61K31/352
Inventor 梅勇罗磊杨莉贺代琼唐建珍舒芬徐刚廖海燕
Owner CHONGQING CONQUER PHARML
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com